Ani Pharmaceuticals (ANIP) Intangibles (2012 - 2026)

Ani Pharmaceuticals (ANIP) has 15 years of Intangibles data on file, last reported at $467.2 million in Q1 2026.

• For the quarter ending Q1 2026, Intangibles fell 13.25% year-over-year to $467.2 million; the trailing twelve-month figure through Mar 2026 stood at $467.2 million (down 13.25% YoY), and the FY2025 full-year result was $479.5 million, down 11.5% from the prior year.
• Intangibles retreated to $467.2 million in Q1 2026, from $479.5 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $569.8 million in Q3 2024 to a low of $4.3 million in Q2 2023.
• A 5-year average of $307.7 million and a median of $264.2 million in 2022 frame the typical range for Intangibles.
• Across the five-year window, Intangibles sank 98.41% in 2023 and jumped 4157.63% in 2024, its largest moves.
• Tracing ANIP's Intangibles over 5 years: stood at $251.6 million in 2022, then slipped by 16.94% to $209.0 million in 2023, then soared by 159.24% to $541.8 million in 2024, then dropped by 11.5% to $479.5 million in 2025, then fell by 2.58% to $467.2 million in 2026.
• Business Quant data shows ANIP's Intangibles at $467.2 million in Q1 2026, $479.5 million in Q4 2025, and $499.8 million in Q3 2025.